Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells

scientific article published on 20 August 2008

Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1159/000151367
P698PubMed publication ID18714168

P50authorQuanhai LiQ39369637
P2093author name stringFangzhou Song
Youquan Bu
Zhengmei Yang
P433issue3-4
P921main subjectesophageal cancerQ372701
P304page(s)198-206
P577publication date2008-08-20
P1433published inOncologyQ2016300
P1476titleSilencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells
P478volume74

Reverse relations

cites work (P2860)
Q38598778Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma
Q30496149Cancer biomarker discovery: the entropic hallmark
Q28076060Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications
Q36071638Current progress of siRNA/shRNA therapeutics in clinical trials
Q47132417Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma
Q90291164Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras
Q57359344Enhancing Gene-Knockdown Efficiency of Poly(-isopropylacrylamide) Nanogels
Q28278655Growth inhibition, morphology change, and cell cycle alterations in NFBD1-depleted human esophageal cancer cells
Q90396711Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
Q39141522Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells
Q92177878Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications
Q42748194MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.
Q39830221Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma
Q37335160Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients
Q28078772PLK1, A Potential Target for Cancer Therapy
Q33829178Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass
Q36105529Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma
Q33662727RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma
Q38966322RNAi-mediated silencing of the Skp-2 gene causes inhibition of growth and induction of apoptosis in human renal carcinoma cells
Q35216353SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis
Q47147377SUMOylation regulates the localization and activity of Polo-like kinase 1 during cell cycle in the silkworm, Bombyx mori.
Q41927888Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death.
Q33514778Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas
Q33564389Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells
Q37386185The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity
Q28548580Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases

Search more.